Vivanta Tablet 49 mg + 51 mg contains a fixed-dose combination of Sacubitril and Valsartan, used for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). This strength is commonly prescribed for patients who have been stabilized on lower doses and require further therapeutic benefit. Vivanta Tablet belongs to the class of angiotensin receptor–neprilysin inhibitors (ARNIs) and plays an important role in improving cardiac function, reducing heart failure–related hospitalizations, and lowering cardiovascular mortality.

Mechanism of Action

Sacubitril inhibits the enzyme neprilysin, leading to increased levels of natriuretic peptides that promote vasodilation, natriuresis, and reduced cardiac workload. Valsartan, an angiotensin II receptor blocker (ARB), counteracts the harmful effects of angiotensin II such as vasoconstriction, sodium retention, and myocardial remodeling. The combined action results in improved hemodynamic balance, reduced strain on the heart, and better overall cardiovascular outcomes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Vivanta Tablet 49 mg + 51 mg is indicated for:

• Treatment of chronic heart failure with reduced ejection fraction

• Patients with symptomatic heart failure who require up-titration from lower doses

• Reduction of risk of cardiovascular death and hospitalization due to heart failure

• Use as a replacement for ACE inhibitors or other ARBs, under medical supervision

Dosage and Administration

The dosage of Vivanta Tablet should be individualized by the treating physician based on the patient’s clinical condition, prior therapy, and tolerance. It is usually taken twice daily, with or without food. Tablets should be swallowed whole with water. Regular monitoring of blood pressure, kidney function, and serum potassium levels is recommended during treatment.

Benefits

• Improves heart function and reduces symptoms of heart failure

• Decreases the risk of hospitalization related to heart failure

• Lowers cardiovascular mortality in patients with HFrEF

• Helps enhance exercise capacity and quality of life

• Fixed-dose combination improves treatment adherence

Possible Side Effects

Vivanta Tablet is generally well tolerated. Some patients may experience:

• Hypotension or dizziness

• Elevated potassium levels (hyperkalemia)

• Impaired kidney function

• Fatigue or headache

Rare but serious side effects such as angioedema require immediate medical attention.

Precautions and Warnings

• Do not use concurrently with ACE inhibitors; a washout period is required

• Use with caution in patients with renal impairment or low blood pressure

• Contraindicated during pregnancy due to risk to the fetus

• Breastfeeding should be discussed with a healthcare provider

• Close medical supervision is necessary during dose adjustments

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Vivanta Tablet may interact with potassium supplements, potassium-sparing diuretics, NSAIDs, and other antihypertensive agents. Patients should inform their physician about all medications they are taking before starting therapy.

Storage

Store Vivanta Tablet 49 mg + 51 mg in a cool, dry place away from direct sunlight. Keep out of reach of children.

Conclusion

Vivanta Tablet 49 mg + 51 mg (Sacubitril + Valsartan) is an effective and well-established therapy for managing chronic heart failure with reduced ejection fraction. When used as directed and under medical supervision, it helps improve heart performance, reduce hospitalization rates, and support better long-term cardiovascular outcomes.